4SC AG: RESMAIN Study Results to be Presented at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 23 September 2023
4SC AG (4SC, FSE Prime Standard: VSC) announced that the results from the RESMAIN Study evaluating resminostat (Kinselby…
4SC AG (4SC, FSE Prime Standard: VSC) announced that the results from the RESMAIN Study evaluating resminostat (Kinselby…
. The European Medicines Agency (EMA) has notified 4SC that it has accepted its Letter of Intent to Submit a Marketing…
4SC AG (4SC, FSE Prime Standard: VSC) has now filed with EMA its letter of intent to file for Marketing Authorization fo…
Resminostat met the primary endpoint in the RESMAIN study, demonstrating a statistically significant improvement in prog…
4SC AG (4SC, FSE Prime Standard: VSC) today published the Q1 Announcement 2023, presenting all material developments up…
4SC AG (4SC, FSE Prime Standard: VSC) today published the financial results for the financial year ended 31 December 202…
4SC AG (4SC, FSE Prime Standard: VSC) today announced that its pre-authorisation eligibility request to the European Med…
The Supervisory Board of 4SC AG (4SC, FSE Prime Standard: VSC) has appointed Kathleen Masch-Wiest as a new member of the…
4SC AG (4SC, FSE Prime Standard: VSC) today provided a business update for the three months ended 30 September 2022, as…
4SC AG (4SC, FSE Prime Standard: VSC) today published its Half-Year Report 2022, presenting all material developments up…